読み込み中
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
前日終値
$7.16
+$0.19 · +2.73%
日中の時刻はETです。市場データは遅延する場合があります。
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
日中レンジ
現在 $7.16
52週レンジ
現在 $7.16
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
34
割高
センチメント
58
まちまち
リスク
39
中程度のリスク
モメンタム
72
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
日中レンジ
現在 $7.16
52週レンジ
現在 $7.16
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|
| 売上高 | 2405万 USD | — | — | — |
| 売上原価 | 349.6万 USD | 315.2万 USD | — | 25万 USD |
| 粗利益 | 2055.4万 USD | −315.2万 USD | — | −25万 USD |
| 研究開発 | 3.86億 USD | 2.66億 USD | 1.38億 USD | 1.01億 USD |
| 販売・一般管理 | 9185.6万 USD | 3520万 USD | 2049.8万 USD | 1254.6万 USD |
| 営業費用 | 4.48億 USD | 2.98億 USD | 1.58億 USD | 1.14億 USD |
| 受取利息 | 1418万 USD | 1202万 USD | 336.8万 USD | 199.2万 USD |
| 減価償却費と償却費 | 349.6万 USD | 315.2万 USD | 128.4万 USD | 25万 USD |
| 営業利益 | −4.27億 USD | −3.01億 USD | −1.58億 USD | −1.14億 USD |
| 純利益 | −2.43億 USD | −2.94億 USD | −1.55億 USD | −1.12億 USD |
会社概要が更新されました 2026年10月11日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI6866.81万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF2160.84万0.02%954億 USD0.05%$235+0.80%
iShares Russell 2000 ETFIWM1442.06万0.02%787.4億 USD0.19%$278.94+0.49%
Vanguard Russell 2000 ETFVTWO989.81万0.05%180億 USD0.06%$112.66+0.50%
State Street SPDR S&P Pharmaceuticals ETFXPH667.03万1.45%4.62億 USD0.35%$64.65+1.60%
iShares Biotechnology ETFIBB520.42万0.05%108.2億 USD0.44%$206.49+3.00%
iShares Russell 2000 Growth ETFIWO511.45万0.04%139.17億 USD0.24%$356.78+0.94%
Vanguard Health Care ETFVHT390.39万0.02%220億 USD0.09%$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOState Street SPDR S&P Pharmaceuticals ETFXPHiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Health Care ETFVHTAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
